BioCentury
ARTICLE | Clinical News

Augment Injectable Bone Graft: Phase III ongoing

December 5, 2011 8:00 AM UTC

In its 3Q11 earnings, BioMimetic said it proposed to expand enrollment to 300 patients in a North American Phase III trial evaluating its Augment Injectable Bone Graft to treat hindfoot fusions. The t...